Business Wire

OCP-TAP approves Adtran’s OSA 5400 TimeCard™ for precise, resilient data center timing

28.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Adtran today announced that the Open Compute Project (OCP) Time Appliance Project (TAP) has approved its OSA 5400 TimeCard™ for data center timing and synchronization. The pluggable device injects Adtran’s Oscilloquartz timing technology into any white box server, solving key challenges in the transition to virtualized environments. The OCP-TAP’s endorsement means data center operators leveraging the OSA 5400 TimeCard to synchronize COTS hardware can be assured of precise, reliable and robust timing as they move to more cost-efficient and scalable network architectures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928894327/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The OSA 5400 TimeCard™ represents a simple route to accurate, reliable and robust data center timing. (Photo: Business Wire)

“We’re pleased to be able to announce that Adtran’s OSA 5400 TimeCard now supports the OCP-TAP driver. It’s an important milestone in our collective quest to advance robust and accurate timing solutions for distributed system use cases. By meeting our framework’s specifications, Adtran is helping us drive standardization and interoperability, accelerating the industry’s shift to open, standardized hardware,” said Ahmad Byagowi, TAP project leader at OCP-TAP. “This pluggable solution represents a simple route to accurate, reliable and robust data center timing. We believe that solutions like the OSA 5400 TimeCard will play a pivotal role in advancing the next generation of scalable and resilient infrastructure.”

Enabling data center operators to efficiently host the most demanding time-sensitive applications, Adtran’s OSA 5400 TimeCard plugs into any free PCIe slot to turn a standard COTS server into a precise PTP grandmaster clock or NTP server. With multiple oscillator options, the solution ensures accurate timing even during extended periods of GNSS disturbances. In combination with Adtran’s Ensemble Sync Director, the OSA 5400 TimeCard provides operational teams with a comprehensive, unified view of their entire timing infrastructure. This enables them to easily manage all elements of their timing network, enhancing control and reliability. What’s more, the OSA 5400 TimeCard has been developed to align fully with the IEEE P3335 standardization, ensuring adaptability and underscoring Adtran’s commitment to industry advancement in a cohesive digital ecosystem.

“We’re proud that our OSA 5400 TimeCard has been validated by OCP-TAP. This card brings our 74 years of expertise in timing and synchronization to standard servers, going beyond the TAP specifications to provide a scalable, fully featured timing solution in a compact half-size PCIe card. It offers a major boost for data center operators looking to embrace open, disaggregated hardware, especially where timing is vital and space is limited. Our OSA 5400 TimeCard ensures seamless, efficient operation of mission-critical and time-sensitive applications,” commented Igal Pinhasov, VP of PLM at Oscilloquartz, Adtran. “As the industry progresses towards agile, cost-effective data center environments, our pluggable timing technology will play a defining role in shaping future architectures.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com

For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye